<DOC>
	<DOCNO>NCT02473289</DOCNO>
	<brief_summary>The purpose study evaluate efficacy sirukumab adjunctive treatment antidepressant therapy ( monoaminergic antidepressant ) sirukumab ( administer 50 milligram ( mg ) subcutaneous ( SC ) injection Day 1 , Day 28 Day 56 12- week double-blind treatment period ) compare adjunctive placebo base change baseline 12-week endpoint depressive symptom measure total score Hamilton Depression Rating Scale ( HDRS ) , participant diagnose Major Depressive Disorder ( MDD ) suboptimal response current standard oral antidepressant therapy screen high sensitivity C-Reactive Protein ( hsCRP ) &gt; =0.300 milligram per deciliter ( mg/dL ) ( International System Units ( SI ) 3.00 mg/L ) . A cohort subject hsCRP &lt; 0.300 milligram per deciliter also enrol allow well understanding relationship CRP clinical change .</brief_summary>
	<brief_title>An Efficacy Safety Study Sirukumab Participants With Major Depressive Disorder</brief_title>
	<detailed_description>A double-blind , placebo-controlled , multicenter study sirukumab adjunctive treatment monoaminergic antidepressant adult major depressive disorder . Participants randomly assign receive either placebo sirukumab 50 milligram ( mg ) ratio 1:1 Day 1 , 28 56 . Participants primarily assess change baseline Hamilton Depression Rating Scale ( HDRS17 ) score Week 12 . Safety monitor throughout study .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>Participants must primary DSM5 diagnosis MDD Must HDRS total score great equal ( &gt; = ) 18 screen predose Day 1 , record remote independent rater must demonstrate improvement &gt; 25 percent ( % ) HDRS total score screen baseline visit Must medically stable basis physical examination , medical history , vital sign , clinical laboratory test 12lead ECG perform screen . If abnormality , participant may include investigator judge abnormalities deviation normal clinically significant . This determination must record subject 's source document initial investigator Participants hypothyroidism stable treatment 3 month prior screen require thyroid stimulate hormone ( TSH ) free thyroxine ( FT4 ) obtain . If TSH value range , FT4 normal , case discuss directly medical monitor subject enrol . If FT4 value range , participant eligible Any current Axis one psychiatric condition , include , limited , MDD current psychotic feature , bipolar disorder ( include lifetime diagnosis ) , obsessivecompulsive disorder , borderline personality disorder , eat disorder ( eg , bulimia , anorexia nervosa ) , schizophrenia ( lifetime ) . The MINI use screen comorbid psychiatric diagnosis . As noted , subject diagnosis comorbid GAD , PostTraumatic Stress Disorder , Persistent Depressive Disorder , ADHD , Social Anxiety Disorder , Panic Disorder without agoraphobia Nicotine/Caffeine Dependence may include , investigator considers MDD primary diagnosis A history alcohol substance use disorder ( abuse/dependence ) within 6 month prior screen ( nicotine caffeine dependence exclusionary ) A current recent ( within past year ) history clinically significant suicidal ideation ( correspond score &gt; = 3 ideation ) suicidal behavior within past year , validate CSSRS screen baseline . Subjects prior suicide attempt sort , history prior serious suicidal ideation/plan carefully screen current suicidal ideation include discretion investigator More 3 fail antidepressant treatment ( adequate dose duration ) current episode depression ( verified MGHATRQ ) Length current major depressive episode &gt; 60 month</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Depressive disorder , major</keyword>
	<keyword>Sirukumab</keyword>
</DOC>